Select Page

ASTHMAInterested in understanding the impact of new product launches such as biologics in severe asthma?

Explore the most recent developments in this therapeutic area using real-world data from anonymized patient charts

Our ASTHMAsyndiTrackTM syndicated study already features data from thousands of anonymized patient charts collected from hundreds of severe asthma prescribers across Europe and can be extended to many more countries.

The assessment provides a comprehensive patient overview: 

  • 4 specific types / phenotypes
  • 4 typical biomarkers
  • 3 detailed lung function tests
  • 3 clinical assessment scales
  • patient treatments (both reliever and controller therapies including Biologics)
  • level of patient involvement in treatment decision

A focus on Biologics, all you need to know about the uptake of Biologics:

  • treatment modalities
  • treatment shares by type and phenotype of patients
  • shares in the most recently started treatments (< 6 months)
  • brand profiles
  • reasons to choose each biologics in actual practice

Xolair    Dupixent    Nucala     Fasenra     Cinqaero

Did you know that?...

  • It takes 10 years on average to become a severe asthma patient after an asthma diagnosis
  • A typical severe asthma patient spends 63 days on oral corticosteroids in a year
  • A large proportion of severe asthma patients experience more than 2 severe exacerbations leading to hospitalization every year

Do you want to know more about...?

  • Reduction of oral corticosteroids usage after biologics prescription in actual life?
  • Decrease in proportion of patients with severe exacerbation after biologics prescription
  • What is the split of patients per phenotype?
  • What is the share of each Biologic per asthma phenotype?
  • Which biologic is the most expected at reducing OCS usage by physicians?
  • What is the intention to expand biologics usage in the near future and which ones?

Example of recent release (contact us for even more recent data):

  • Collection up to December 2021
  • 80 HCPs = 71 Pulmonologists and 9 Pediatricians/Pneumo-pediatricians in France
  • 613 real-world patient charts

  • We also have Asthma syndicated results from previous waves conducted in Italy, Spain, the UK, Germany, the Netherlands, and are ready to expand to any country on request: check with us.

More information about our Severe Asthma syndicated study including:

  • Objectives 
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves and countries

Fill in the form and we will be in touch shortly. 👆

Go further with the data and discover an example of a Digital & Interactive Dashboard (DID) created by APLUSA

We take here the example of a patient share tracker in Cancer X syndiTrackTM.
The dashboard is built around 6 variables: the country, the treatment start date, the treatment line, the product or regimen, risk factors and market share.

In total, there are many advantages of using this DID:
- your data is available online and can be easily shared within your organization,
- you can create your own views instead of manipulating a large number of powerpoint slides,
- you always have the latest data available, no update problems,
- the data is available on your dashboard much earlier in the data collection,
- the report will be more focused on key insights and storytelling than on data production.

👇 Test our live demo here! 👇